Cleveland Clinic's Cole Eye Institute receives $310,000 grant

Cleveland, OH-The Cleveland Clinic's Cole Eye Institute and biotechnology firm Arteriocyte Inc. have been awarded a $310,000 grant to study the treatment of eye disease.

One of the main focuses of the research is to treat diabetic retinopathy.

According to the American Academy of Ophthalmology, the disease is the leading cause of blindness among working Americans.

The study will evaluate whether a cellular therapy product by Arteriocyte could prevent the initial vaso-degenerative phase of the disease.